Accelerate Drug Discovery With AI-Ready Scientific Data
Practical insights and real-world examples for scaling AI across pharmaceutical R&D.
AI is transforming pharmaceutical R&D—but only when the data behind it is complete, consistent, and connected. Many organizations struggle to scale promising AI pilots because scientific data remains fragmented across systems and sources.
This collection explores how industry leaders are solving that challenge. Discover how stronger data foundations improve prediction accuracy, accelerate candidate prioritization, and support faster, more confident R&D decisions. You’ll also see how a custom AI training dataset helped improve synthesis prediction performance in a real-world discovery workflow.
White Paper: How Data Limitations Hold Back AI in Pharma R&D — and How Organizations Can Reverse the Trend
AI promises faster pharmaceutical discovery, but fragmented and inconsistent data often prevents models from delivering reliable results. This white paper explores the hidden data challenges limiting AI adoption and outlines practical strategies to build a trusted, AI-ready scientific data foundation that improves prediction accuracy and accelerates R&D decision-making.
DownloadCase Study: Custom AI Training Dataset Establishes New Standards in Regioselectivity Prediction Accuracy
When ChemLex needed more reliable data to train its AI model for synthesis planning, open-access datasets fell short. This case study shows how a custom-curated training dataset dramatically improved regioselectivity prediction accuracy—helping chemists streamline synthesis planning, reduce material waste, and accelerate drug discovery workflows.
DownloadTurning untapped pharma R&D data into predictive power
Artificial intelligence has the potential to transform pharmaceutical R&D—but only if the data fueling it is complete, consistent, and connected. This white paper outlines three actionable steps to prepare your data for trustworthy AI insights and faster innovation.
DownloadHow CAS Custom API solutions help Calibr-Skaggs Accelerate Drug Discovery
For drug discovery organizations like Calibr-Skaggs, prioritizing the right compounds is vital for efficiency and speed to market. This case study explores three key challenges hindering their discovery pipeline and the tailored solution that accelerated progress toward life-saving treatments.
Download